Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2025-12-25 @ 1:23 AM
NCT ID:
NCT05668793
Eligibility Criteria:
Inclusion Criteria:
* Those who meet any of the following conditions can be enrolled into the hepatocellular carcinoma group：
1. Patients who have suspected placeholder lesions in the liver area after existing examinations and plan to undergo multi-parameter MRI, CT dynamic enhancement scans, ultrasound imaging or enhanced magnetic resonance scans with the hepatocyte-specific contrast agent disodium gadolinium cerate (Gd-EOB-DTPA)；
2. Patients who are highly suspected of liver cancer diagnosed by multi-parameter MRI, CT dynamic enhancement scan, ultrasound contrast, liver cell-specific contrast agent disodium gadolinium cerate (Gd-EOB-DTPA) enhanced magnetic resonance scan or puncture biopsy, before treatment and surgery；
* Those who meet any of the following conditions can be enrolled into the negative group：
1. Patients with benign liver diseases (including cirrhosis, hepatitis, fatty liver, liver adenoma, liver cyst, etc.).
2. Untreated patients with other digestive system tumors (including stomach cancer, colorectal cancer, esophageal cancer, pancreatic cancer, gallbladder/duct cancer, etc.) and patients with non-digestive system tumors (including lung cancer, thyroid cancer, cervical cancer, endometrial cancer, breast cancer, prostate cancer, urothelial cancer, etc.).
Exclusion Criteria:
Those who meet any of the following conditions should be excluded：
1. Patients with hepatocellular carcinoma who have received anti-tumor treatments such as radiotherapy/chemotherapy；
2. Hepatocellular carcinoma patients suffering from other malignant tumors at the same time；
3. Samples that are not kept as required or samples of hemolysis；
4. The sample size collected does not meet the testing requirements；
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05668793
Study Brief:
Protocol Section:
NCT05668793